REG - GSK PLC - GSK Annual Report 2022 on Form 20-F

GSKAnnouncement

10/03/2023 16:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230310:nRSJ6376Sa&default-theme=true

RNS Number : 6376S  GSK PLC  10 March 2023

Issued: 10 March 2023, London UK

 

GSK plc

Annual Report 2022 on Form 20-F

 

In accordance with Section 203.01 of the New York Stock Exchange Listed
Company Manual, GSK plc ("GSK") announces that on 10 March 2023 it filed with
the Securities and Exchange Commission an Annual Report on Form 20-F that
included audited financial statements for the year ended 31 December 2022.
GSK's 2022 Annual Report on Form 20-F is available online at GSK's website at
www.gsk.com/corporatereporting (http://www.gsk.com/corporatereporting) and
also online at www.sec.gov (http://www.sec.gov) .

A hard copy version of the GSK 2022 Annual Report, together with the Notice of
Annual General Meeting will be available on or about 27 March 2023.

Shareholders have the ability to receive, upon request, a hard copy version of
GSK's complete audited financial statements for the year ended 31 December
2022, free of charge, by either:

 (i)    writing to Equiniti Limited, our registrars in the UK, at the following
        address: Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex
        BN99 6DA, or by telephone on +44 (0)371 384 2991 (please use the area code if
        calling from outside the UK);

 (ii)   writing to J.P. Morgan Chase Bank, N.A. our ADR depositary in the US, at the
        following address: EQ Shareowner Services, P.O. Box 64504, St. Paul, MN
        55164-0504, or by telephone on +1 877 353 1154 (US toll free) or +1 651 453
        2128 (outside the US); or

 (iii)  contacting the GSK Response Center in the USA at +1 888 825 5249 (US toll
        free).

 

 

 

Victoria Whyte

Company Secretary

10 March 2023

 

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described under
Item 3.D 'Risk factors" in the company's Annual Report on Form 20-F for 2022,
GSK's Q4 Results for 2022 and any impacts of the COVID-19 pandemic.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACSSFDFMSEDSEED